12:00 AM
 | 
Sep 14, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Soluble Beta Glucan: Completed Phase III enrollment

Biotec Pharmacon completed enrollment of 130 patients in a double-blind, placebo-controlled, European Phase III trial. SBG has Orphan Drug designation...

Read the full 80 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >